TY - JOUR
T1 - Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands
AU - Franken, Margreet G.
AU - Leeneman, Brenda
AU - Jochems, Anouk
AU - Schouwenburg, Maartje G.
AU - Aarts, Maureen J. B.
AU - van Akkooi, Alexander C. J.
AU - van den Berkmortel, Franchette W. P. . J.
AU - van den Eertwegh, Alfonsus J. M.
AU - de Groot, Jan Willem B.
AU - van der Hoeven, Koos J. M.
AU - Hospers, Geke A. P.
AU - Kapiteijn, Ellen
AU - Koornstra, Rutger
AU - Kruit, Wim H. J.
AU - Louwman, Marieke W. J.
AU - Piersma, Djura
AU - van Rijn, Rozemarijn S.
AU - Suijkerbuijk, Karijn P. M.
AU - ten Tije, Albert J.
AU - Vreugdenhil, Gerard
AU - Wouters, Michel W. J. M.
AU - van Zeijl, Michiel
AU - Haanen, John B. A. G.
AU - Uyl-de Groot, Carin A.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to individual patient resource use. A total of 807 patients who were diagnosed between July 2012 and July 2015 received ipilimumab in Dutch practice. The mean (median) episode duration was 6.27 (4.61) months (computed from the start of ipilimumab until the start of a next treatment, death, or the last date of follow-up). The average total healthcare costs amounted to Euro81484, but varied widely (range: Euro18131-Euro160002). Ipilimumab was by far the most important cost driver (Euro73739). Other costs were related to hospital admissions (Euro3323), hospital visits (Euro1791), diagnostics and imaging (Euro1505), radiotherapy (Euro828), and surgery (Euro297). Monthly costs for resource use other than ipilimumab were Euro1997 (SD: Euro2629). Treatment-naive patients (n=344) had higher total costs compared with previously-treated patients (n=463; Euro85081 vs. Euro78811). Although patients with colitis (n=106) had higher costs for resource use other than ipilimumab (Euro11426) compared with patients with other types of immune-related adverse events (n=90; Euro9850) and patients with no immune-related adverse event (n=611; Euro6796), they had lower total costs (Euro76075 vs. Euro87882 and Euro81480, respectively). In conclusion, this nation-wide study provides valuable insights into the healthcare costs of advanced cutaneous melanoma patients who were treated with ipilimumab in clinical practice. Most of the costs were attributable to ipilimumab, but the costs and its distribution varied considerably across subgroups.
AB - There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to individual patient resource use. A total of 807 patients who were diagnosed between July 2012 and July 2015 received ipilimumab in Dutch practice. The mean (median) episode duration was 6.27 (4.61) months (computed from the start of ipilimumab until the start of a next treatment, death, or the last date of follow-up). The average total healthcare costs amounted to Euro81484, but varied widely (range: Euro18131-Euro160002). Ipilimumab was by far the most important cost driver (Euro73739). Other costs were related to hospital admissions (Euro3323), hospital visits (Euro1791), diagnostics and imaging (Euro1505), radiotherapy (Euro828), and surgery (Euro297). Monthly costs for resource use other than ipilimumab were Euro1997 (SD: Euro2629). Treatment-naive patients (n=344) had higher total costs compared with previously-treated patients (n=463; Euro85081 vs. Euro78811). Although patients with colitis (n=106) had higher costs for resource use other than ipilimumab (Euro11426) compared with patients with other types of immune-related adverse events (n=90; Euro9850) and patients with no immune-related adverse event (n=611; Euro6796), they had lower total costs (Euro76075 vs. Euro87882 and Euro81480, respectively). In conclusion, this nation-wide study provides valuable insights into the healthcare costs of advanced cutaneous melanoma patients who were treated with ipilimumab in clinical practice. Most of the costs were attributable to ipilimumab, but the costs and its distribution varied considerably across subgroups.
KW - advanced cutaneous melanoma
KW - colitis
KW - healthcare costs
KW - immune-related adverse events
KW - ipilimumab
KW - CLINICAL-PRACTICE GUIDELINES
KW - METASTATIC MELANOMA
KW - ECONOMIC BURDEN
KW - FOLLOW-UP
KW - DACARBAZINE
KW - DIAGNOSIS
KW - TOXICITY
KW - FRANCE
KW - TRIALS
U2 - 10.1097/CAD.0000000000000628
DO - 10.1097/CAD.0000000000000628
M3 - Article
SN - 0959-4973
VL - 29
SP - 579
EP - 588
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 6
ER -